Thync Before You Act – A New Wearable Device Made for 'The Donald'
If you thought people looked foolish wearing Google Glass, wait until you see one of your coworkers sticking a white piece of plastic on her forehead, hooked around her ear. I learned about Thync, a $300 electric gizmo, reading Geoffrey Fowler’s Wall Street Journal column Tuesday.
Fowler tested it, so I don’t have to, but I just know I’ll be seeing this piece of wearable tech around town among the gadgerati I sometimes hang out with. Thync’s unique selling proposition is vibes, uncommonly known as transdermal electrical neuromodulation. Translation—it’s a low-grade form of shock therapy. The company says they’ve tested the device over years of research with their neuroscientists and engineers to give us Calm vibes or Energy vibes.
You’ll have to go to Fowler’s story to view a graphic of how this dildo for the brain actually functions, but Folwer describes the Energy vibe this way: “The sensation is like drinking an espresso, accompanied by a tingle of prickly heat behind the ear.” He compares the hour-long Calm vibe to having a glass of wine.
Like everything else related to wearable tech and the Internet of Things, the company is well funded by Silicon Valley venture capital firms, which are apparently looking for the next Fitbit. And why not? Brain fitness. I know a few people who could benefit from Thync if it works as promised.
Let’s start by getting the company to give one to Donald Trump, set it permanently on the Calm setting, and turn up the juice.
Top Reads from The Fiscal Times:
- Six Amazing Features Hidden in Your Smartphone
- Facebook Must Hand Over NY Users' Info to Prosecutors
- The Incredible Disappearing American-Made Car
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
